Zobrazeno 1 - 10
of 165
pro vyhledávání: '"Aishah M"'
Autor:
Mohammed A Alzahrani, Mohammed A Alfahadi, Meshref A Alshehri, Abdulaziz H Alamri, Eman A Almahjani, Aishah M Alahmari, Abdullah A Al-Shahrani, Abdulaziz S Alshahrani, Ibrahim M Almanjahi, Abdullah M Alqarni
Publikováno v:
The Saudi Journal of Gastroenterology, Vol 30, Iss 2, Pp 96-102 (2024)
Background: Esophageal motility disorders (EMDs) can significantly impact patients' quality of life. The Chicago Classification (CC) was developed as a robust framework to enable clinicians to better understand and classify the nature of motility dis
Externí odkaz:
https://doaj.org/article/027c91945573422daf775ab2e629a13c
Publikováno v:
Heliyon, Vol 9, Iss 6, Pp e17058- (2023)
Spebrutinib is a new Bruton tyrosine kinase inhibitor developed by Avila Therapeutics and Celgene. Spebrutinib (SPB) is currently in phase Ib clinical trials for the treatment of lymphoma in the United States. Preliminary in-silico studies were first
Externí odkaz:
https://doaj.org/article/c844c6556d144888acaeafd44bc0ff4d
Publikováno v:
Molecules, Vol 28, Iss 10, p 4225 (2023)
Fenebrutinib is an orally available Bruton tyrosine kinase inhibitor. It is currently in multiple phase III clinical trials for the management of B-cell tumors and autoimmune disorders. Elementary in-silico studies were first performed to predict sus
Externí odkaz:
https://doaj.org/article/89e56f63b2aa4f13b9ab39b31de340e9
Publikováno v:
Separations, Vol 10, Iss 5, p 302 (2023)
Fenebrutinib (GDC-0853; FNB) is an oral small molecule that was developed by Roche Pharmaceuticals to slow multiple sclerosis progression. FNB is a reversible bruton tyrosine kinase (BTK) inhibitor, which showed the maximum potency of BTK inhibitors
Externí odkaz:
https://doaj.org/article/dd2c40c014ef4924a81d02bde02f59ea
Publikováno v:
Separations, Vol 10, Iss 5, p 278 (2023)
Gilteritinib (Xospata®) is a tyrosine kinase inhibitor (TKI) that works by inhibiting numerous receptor tyrosine kinases, involving AXL and FMS-like tyrosine kinase 3 (FLT3). Gilteritinib (GTB) was approved (28 November 2018) by the USFDA for the tr
Externí odkaz:
https://doaj.org/article/80008779185147a8aca8a56b702b0185
Publikováno v:
Separations, Vol 10, Iss 4, p 247 (2023)
Capmatinib (CMB) is an orally bioavailable mesenchymal–epithelial transition (MET) inhibitor approved by the US-FDA to treat metastatic non-small cell lung cancer (NSCLC) patients, with MET exon 14 skipping mutation. The current study aimed to esta
Externí odkaz:
https://doaj.org/article/ad0c004eea5a4c5dac58bc3d9f94fd4d
Publikováno v:
Molecules, Vol 28, Iss 3, p 978 (2023)
Quinazolines are nitrogen-containing heterocycles that consist of a benzene ring fused with a pyrimidine ring. Quinazolinones, oxidized quinazolines, are promising compounds with a wide range of biological activities. In the pharmaceutical field, qui
Externí odkaz:
https://doaj.org/article/a62a927887fd40e7b88cce8cd34d0cef
Autor:
Najim Z. Alshahrani, Mohammed R. Algethami, Abdullah M. Alarifi, Faris Alzahrani, Eman A. Alshehri, Aishah M. Alshehri, Haytham Abdulwhab Sheerah, Abdelaziz Abdelaal, Ranjit Sah, Alfonso J. Rodriguez-Morales
Publikováno v:
Vaccines, Vol 10, Iss 12, p 2099 (2022)
The growing incidence of human monkeypox cases emphasizes the significance of prevention, early detection, and prompt responses for healthcare providers. The aim of this study was to assess the knowledge and attitudes toward monkeypox infection among
Externí odkaz:
https://doaj.org/article/886c7aeda1d74aeb9e299ba3f303f563
Autor:
Idros, Noorhayati, Sidek, Lariyah Mohd, Rahim, Nur Anis Aishah M., Noh, Nurshahira Mohd, Abdelkader, Amr M., Mohiyaden, Hairun Aishah, Basri, Hidayah, Zawawi, Mohd Hafiz Bin, Ahmed, Ali Najah
Publikováno v:
In Ecological Indicators March 2024 160
Autor:
Alsibaee, Aishah M., Aljohar, Haya I., Attwa, Mohamed W., Abdelhameed, Ali Saber, Kadi, Adnan A.
Publikováno v:
In Heliyon June 2023 9(6)